化合物KY-02327 T39508

Product Introduction
Bioactivity


英文名: KY-02327

描述: KY-02327 是 KY-02061的一种类似物，具有代谢稳定性。KY-02327是Dishevelled (Dvl)-CXXC5相互作用抑制剂。KY-02327激活Wnt/β-catenin 途径，从而促进成骨细胞分化。

体外活性: KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner [1]. KY-02327 (1-10 μM) increases the mRNA levels of collagen 1a ( Col1a ) and osteocalcin ( OCN ) which are the osteoblast differentiation markers[1].

体内活性: KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) successfully rescues bone loss in the ovariectomized (OVX) mouse model which is potential candidate for the development of bone anabolic anti-osteoporosis drug[1] . Animal Model: 8-week-old female BL6 mice (ovariectomized (OVX)-induced osteoporosis model mice) [1] Dosage: 20 mg/kg Administration: P.o.; administered for 5 sequential days per week for 4 weeks Result: Newly formed bones which labeled with calcein were decreased in the femur of vehicle‐treated OVX mice.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 100 mg/mL (267.77 mM)


关键字: Wnt | CXXC5 | KY-02327 | osteoblast | differentiation | inhibit | KY 02327 | anti-osteoporosis | Dishevelled | bone | KY02327 | Inhibitor | anabolic

相关库: Bioactive Compounds Library Max | Inhibitor Library | PPI Inhibitor Library | Bioactive Compound Library

化合物KY-02327 T39508信息由TargetMol中国为您提供，如您想了解更多关于化合物KY-02327 T39508报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途